Related Experiment Video
Updated: May 3, 2026
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment
Published on: April 25, 2025
Synthesis and therapeutic evaluation of an aptide-docetaxel conjugate targeting tumor-associated fibronectin
Hyungjun Kim1, Yonghyun Lee2, In-Hyun Lee2
1School of Life Sciences, Gwangju Institute of Science and Technology, 123 Cheomdangwagi-ro, Gwangju 500-712, Republic of Korea.
Abstract:
Targeted delivery of anticancer drugs to tumors has attracted considerable research interest because of its potential to reduce adverse toxicity while improving therapeutic efficacy. In this study, we synthesized and evaluated the therapeutic efficacy of a conjugate of a high-affinity peptide (aptide) and the anticancer drug docetaxel (DTX). A fibronectin extra domain B (EDB)-specific aptide (APTEDB) was used as a cancer-specific targeting ligand. An APTEDB-DTX conjugate was synthesized from an alkyne-modified aptide and azide-modified DTX via click chemistry. A microscopy study revealed selective binding of dye-labeled APTEDB to EDB-overexpressing cancer cells. The cytotoxicity of the conjugate toward EDB-overexpressing murine lung carcinoma (LLC) and human glioblastoma (U87MG) was similar to that of free DTX. In a pharmacokinetic study, APTEDB-DTX formulated with PEG400/ethanol(5%) exhibited a circulation half-life similar to that of a Tween-80/ethanol formulation of parent DTX. Finally, an evaluation of intravenously injected APTEDB-DTX in mice bearing EDB-positive tumors showed that APTEDB-DTX inhibited the growth of both LLC allograft and U87MG xenograft tumors with an efficacy better than the parent-DTX formulation but with much lower toxicity, as evidenced by reduced body weight loss. Taken together, these results indicate that the aptide-drug conjugate system described here may hold potential as a targeted therapy regimen.
Insights
Researchers developed an aptide-docetaxel conjugate for targeted cancer therapy. This targeted drug delivery system effectively inhibited tumor growth in mice with reduced toxicity compared to traditional docetaxel treatments.
Area of Science:
- Biochemistry
- Oncology
- Nanotechnology
Background:
- Targeted drug delivery aims to enhance anticancer efficacy and minimize systemic toxicity.
- Peptide-drug conjugates offer a promising strategy for site-specific drug administration.
Purpose of the Study:
- To synthesize and evaluate a novel conjugate linking a fibronectin extra domain B (EDB)-specific aptide (APTEDB) with the anticancer drug docetaxel (DTX).
- To assess the targeted delivery, cytotoxicity, pharmacokinetics, and in vivo therapeutic efficacy of the APTEDB-DTX conjugate.
Main Methods:
- Synthesis of APTEDB-DTX conjugate using click chemistry.
- Microscopy to confirm selective binding of dye-labeled APTEDB to EDB-overexpressing cancer cells.
- In vitro cytotoxicity assays on EDB-overexpressing cancer cell lines (LLC and U87MG).
- Pharmacokinetic studies comparing APTEDB-DTX with free DTX.
- In vivo efficacy studies in mice bearing EDB-positive LLC allografts and U87MG xenografts.
Main Results:
- Selective binding of APTEDB to EDB-positive cancer cells was confirmed.
- The APTEDB-DTX conjugate demonstrated comparable cytotoxicity to free DTX in vitro.
- Pharmacokinetic profiles showed similar circulation half-lives for both formulations.
- In vivo studies revealed superior tumor growth inhibition and significantly reduced toxicity (body weight loss) for APTEDB-DTX compared to parent DTX.
Conclusions:
- The developed aptide-drug conjugate system shows potential for targeted cancer therapy.
- APTEDB-DTX offers improved therapeutic efficacy and reduced side effects, warranting further investigation as a novel treatment modality.
More Related Videos
10:46A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
